AstraZeneca Treasury Limited completed the acquisition of Gracell Biotechnologies Inc. from a group of shareholders.
Sebastian L. Fain, Zheng (Jonathan) Zhou, Jeff Jay, Nicole Foster, Sarah Ghulamhussain, Stephanie Chiu, May Smith, Claude Stansbury, Mary Lehner, Simon Priddis, Jenny Leahy, Ninette Dodoo, Laura Onken, Christine Laciak, Stephanie Brown Cripps, Christine Lyon and Brock Dahl of Freshfields Bruckhaus Deringer US LLP, RuiMin Law Firm and Maples Group acted as legal advisors to AstraZeneca Treasury Limited. Rama Padmanabhan and Rowook Park, Will Cai, Patrick Loofbourrow and Jie Zhang of Cooley LLP, AllBright Law Offices and Harney Westwood & Riegels acted as legal advisors and Centerview Partners LLC acted as financial advisor, and provided fairness opinion to Gracell Biotechnologies Inc. In connection with Centerview?s services as the financial advisor to the Board of Directors, Gracell has agreed to pay Centerview an aggregate fee of approximately $24 million, $1 million of which was payable upon the rendering of Centerview?s opinion and the remainder of which is payable contingent upon consummation of the transaction. Mackenzie Partners, Inc. will be paid its customary fee of approximately $12,500, plus out-of-pocket expenses for its proxy solicitation services.
AstraZeneca Treasury Limited completed the acquisition of Gracell Biotechnologies Inc. (NasdaqGS:GRCL) from a group of shareholders on February 22, 2024. As a part of closing trading of the ADSs of Gracell Biotechnologies has been suspended on the Nasdaq Global Select Market (?Nasdaq?).